Return on Equity (ROE): 14.11%
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 14.11% is 56% below its 5-year average of 32.27%, near the low end of its 5-year range (13.49%–94.02%).
As of Monday, June 29, 2026. 35.38% below its 12-month average of 21.84%.
GEHC Return on Equity (ROE) Chart
Annual fiscal-year return on equity; no daily interpolation.
GEHC Average Return on Equity (ROE) Chart
GEHC Current vs Average Return on Equity (ROE) Chart
GEHC Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
14.11%
RETURN ON EQUITY (ROE) AVG TTM
21.84%
RETURN ON EQUITY (ROE) AVG 3Y
21.53%
RETURN ON EQUITY (ROE) AVG 5Y
32.27%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-35.38%
CURRENT VS 3Y AVG
-34.47%
CURRENT VS 5Y AVG
-56.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GEHC Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. (GEHC) | $29.91B | 14.11% | 21.84% | 21.53% | 32.27% |
| ResMed Inc. (RMD)vs › | $29.05B | 23.41% | 22.23% | 22.34% | 21.79% |
| Zoetis Inc. (ZTS)vs › | $31.88B | 81.75% | 66.19% | 56.82% | 52.60% |
| Biogen Inc. (BIIB)vs › | $31.89B | 7.36% | 8.42% | 11.86% | 16.52% |
| IQVIA Holdings Inc. (IQV)vs › | $31.90B | 22.26% | 21.77% | 21.17% | 17.55% |
| Veeva Systems Inc. (VEEV)vs › | $27.84B | 12.89% | 12.42% | 12.32% | 13.45% |
| Centene Corp. (CNC)vs › | $32.44B | -30.07% | -10.46% | -1.37% | 1.10% |
| DexCom, Inc. (DXCM)vs › | $27.07B | 31.47% | 28.93% | 25.01% | 22.95% |
| Medline Inc. (MDLN)vs › | $32.87B | 8.55% | 9.02% | 4.86% | 4.86% |
| Moderna, Inc. (MRNA)vs › | $26.69B | -43.12% | -32.64% | -13.90% | 0.25% |
Return Analysis
ROE
14.1%
ROA
4.0%
Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for GE HealthCare Technologies Inc. (GEHC)?
- The return on equity (ROE) for GEHC stock is 14.11%.
- Is GE HealthCare Technologies Inc.'s return on equity (ROE) high or low?
- The return on equity (ROE) of 14.11% is 56% below its 5-year average of 32.27%, near the low end of its 5-year range (13.49%–94.02%).
- What is the TTM average return on equity (ROE) for GE HealthCare Technologies Inc. (GEHC)?
- The TTM average return on equity (ROE) for GEHC stock is 21.84%.
- What is the 3Y average return on equity (ROE) for GE HealthCare Technologies Inc. (GEHC)?
- The 3Y average return on equity (ROE) for GEHC stock is 21.53%.
- What is the 5Y average return on equity (ROE) for GE HealthCare Technologies Inc. (GEHC)?
- The 5Y average return on equity (ROE) for GEHC stock is 32.27%.
GEHC Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 20.08% |
| 2024-12-31 | 23.59% |
| 2023-12-31 | 21.98% |
| 2022-12-31 | 20.48% |
| 2021-12-31 | 13.49% |
| 2020-12-31 | 94.02% |
| 2019-12-31 | 0.00% |
Related Metrics
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini